The diagnosis and treatment of human papillomavirus-mediated genital lesions

Cutis

Volumn 79, Issue 4 SUPPL., 2007, Pages 5-10

  Brodell, Lindsey Ann ^a,b,d   Mercurio, Mary Gall ^a,b,d   Brodell, Robert T ^a,b,c,d,e  

^a Department of Dermatology ^*

^b UNIVERSITY OF ROCHESTER   (United States)

^c Department of Internal Medicine

^d NORTHEAST OHIO MEDICAL UNIVERSITY   (United States)

^e CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOQUINOLINE DERIVATIVE; IMIQUIMOD; IMMUNOLOGICAL ADJUVANT; KERATOLYTIC AGENT; PODOPHYLLOTOXIN;

ARTICLE; CONDYLOMA ACUMINATUM; DIFFERENTIAL DIAGNOSIS; DRUG SELF ADMINISTRATION; HUMAN;

ADJUVANTS, IMMUNOLOGIC; AMINOQUINOLINES; CONDYLOMATA ACUMINATA; DIAGNOSIS, DIFFERENTIAL; HUMANS; KERATOLYTIC AGENTS; PODOPHYLLOTOXIN; SELF ADMINISTRATION;

EID: 34248330026     PISSN: 00114162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Scheinfeld N, Lehman DS. An evidence-based review of medical and surgical treatments of genital warts. Dermatol Online J. March 2006;12:5.
2. Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines 2006. Available at: http://www.cdc.gov/std/treatment/2006/ genital-warts.htm. Accessed February 1, 2007.
3. Datta SD, Koutsky L, Douglas J, et al. Sentinel surveillance for human papillomavirus among women in the United States, 2003-2004. In: Program and abstracts of the 16th Biennial Meeting of the International Society for Sexually Transmitted Diseases Research; July 10-13, 2005; Amsterdam, Netherlands. Abstract MO-306.
4. Datta SD, Koutsky L, Ratelle S, et al. Type-specific high-risk HPV prevalence from the HPV sentinel surveillance project, US, 2003-2005. In: Program and abstracts of the International Human Papillomavirus Meeting; September 1-7, 2006; Prague, Czech Republic. Abstract P-099.
5. Villa LL, Costa RL, Petta CA, et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multlcentre phase II efficacy trial. Lancet Oncol. 2005;6:271-278.
6. Larsen SA, Steiner BM, Rudolph AH, Laboratory diagnosis and Interpretation of tests for syphilis. Clin Microbiol Rev. 1995;8:1-21
7. Macnab JC, Walkinshaw SA, Cordiner JW, et al. Human papillomavirus in clinically and histologically normal tissue in patients with genital cancer. N Engl J Med. 1986;315:1052.1058.
8. Beutner KR, Conant MA, Frledman-Klen AE, et al. Patient-applied podofilox for treatment of genital warts, Lancet. 1989;1:831-834.
9. Kirby P, Dunne A, King DH, et al. Double-blind randomized clinical trial of self-administered podofilox solution versus vehicle in the treatment of genital warts. Am J Med. 1990;88:465.469.
10. Baker DA, Douglas JM Jr, Buntin DM, et al. Topical podofilox for the treatment of condylomata acuminate In women. Obstet Gynecol. 1990;76:656-659.
11. Greenberg MD, Rutledge LH, Reid R, et al. A double-blind, randomized trial of 0.5% podofilox and placebo for the treatment of genital warts in women. Obstet Gynecol. 1991;77:735-739.
12. von Krogh G, Hellberg D, Self-treatment using a 0.5% podophyllotoxin cream of external genital condylomata acuminata in women: a placebo controlled, double-blind study. Sex Transm Dis. 1992;19:170-174.
13. Bonnez W, Elswick RK Jr, Bailey-Farchione A, et al. Efficacy and safety of 0.5% podofilox solution in the treatment and suppression of anogenital warts. Am J Med. 1994;96:420-425.
14. Strand A, Brinkeborn RM, Siboulet A. Topical treatment of genital warts in men, an open study of podophyllotoxin in cream compared with solution. Genitourin Med. 1995;71:387-390.
15. Petersen CS, Agner T, Ottevanger V, et al. A single-blind study of podophyllotoxin cream 0.5% and podophyllotoxin solution 0.5% in male patients with genital warts. Genitourin Med. 1995;71:391-392.
16. Claesson U, Lassus A, Happonen H, et al. Topical treatment of venereal warts: a comparative open study of podophyllotoxin cream versus solution. Int J STD AIDS. 1996;7:429-434.
17. Tyring S, Edwards L, Cherry LK, et al. Safety and efficacy of 0.5% podofilox gel in the treatment of anogenital warts. Arch Dermatol. 1998;134:33-38.
18. Bhattacharjee P, Brodell RT. Podophillin. In: Brodell RT, Johnson AM, eds. Warts: Diagnosis and Management: An Evidence-Based Approach. New York, NY: Martin Dunitz; 2003:77-90.
19. Gaspari AA. Mechanism of action and other potential roles of an immune response modifier. Cutis. 2007;79 (suppl 4):36-45.
20. Edwards L, Ferenczy A, Eron L, et al. Self-administered topical 5% imiquimod cream for external anogenital warts. HPV Study Group. Human PapillomaVirus. Arch Dermatol. 1998;134:25-30.
21. Beutner KR, Tyring SK, Trofatter KF Jr, et al. Imiquimod, a patient-applied immune response modifier for the treatment of external genital warts. Antimicrob Agents Chemother. 1998;42:789-794.
22. Beutner KR, Spruance SL, Houghton AJ, et al. Treatment of genital warts with an immune response modifier (imiquimod). J Am Acad Dermatol. 1998;38:230-239.
23. Fife KH, Ferenczy A, Douglas JM, et al. Treatment of external genital warts in men using 5% imiquimod cream applied three times a week, once daily, twice daily, or three times a day. Sex Transm Dis. 2001;28:226-231.
24. Buck HW, Fortier M, Knudsen J, et al. Imiquimod 5% cream in the treatment of anogenital warts in female patients. J Dermatol. 2004;31:627-631.
25. Sauder DN, Skinner RB, Fox TL, et al. Topical imiquimod 5% cream as an effective treatment for external genital and perianal warts in different patient populations. Sex Transm Dis. 2003;30:124-128.
26. Carrasco D, vander Strafen M, Tyring SK. Treatment of anogenital warts with imiquimod 5% cream followed by surgical excision of residual lesions. J Am Acad Dermatol. 2002;47(suppl 4):S212-S216.
27. Friedman-Kien AE, Eron LJ, Conant M, et al. Natural interferon alfa for treatment of condylomata acuminata. JAMA. 1988;259:533-538.
28. Alam M, Stiller M. Direct medical costs for surgical and medical treatment of condylomata acuminata. Arch Dermatol. 2001;137:337-341.
29. Langley PC, Tyring SK, Smith MH. The cost effectiveness of patient-applied versus provider-administered intervention strategies for the treatment of external genital warts. Am J Manag Care. 1999;5:69-77.
30. Housman TS, Jorizzo JL. Anecdotal reports of 3 cases illustrating a spectrum of resistant common warts treated with cryotherapy followed by topical imiquimod and salicylic acid. J Am Acad Dermatol. 2002;47(suppl 4): S217-S220.